Antirheumatic drugs
MANAGEMENT OF RHEUMATOID ARTHRITIS: SPECIAL CONSIDERATION FOR BIOLOGIC DISEASE MODIFYING ANTIRHEUMATIC DRUGS
... Rheumatoid arthritis (RA) is a progressive chronic inflammatory disease affecting 0.5–1.0% of the adult population worldwide. Due to the damages caused by this autoimmune disease, new biologic therapies, particularly the ...
7
Kinase inhibitors: a new class of antirheumatic drugs
... Abstract: The outlook for patients with rheumatoid arthritis has improved significantly over the last three decades with the use of disease-modifying antirheumatic drugs. However, despite the use of ...
6
VZV specific T cell levels in patients with rheumatic diseases are reduced and differentially influenced by antirheumatic drugs
... matic drugs such as conventional and biological disease-modifying antirheumatic drugs (cDMARDs and bDMARDs, ...of antirheumatic medication on VZV-specific cellular immunity are ...and ...
12
Eligibility criteria for biologic disease modifying antirheumatic drugs in axial spondyloarthritis: going beyond BASDAI
... Objectives To compare definitions of high disease activity of the ankylosing spondylitis Disease activity score (asDas) and Bath ankylosing spondylitis Disease activity index (BasDai) in selecting patients for treatment ...
8
Ixekizumab efficacy and safety with and without concomitant conventional disease modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD) naïve patients with active psoriatic arthritis (PsA): results from SPIRIT P1
... disease-modifying antirheumatic drugs (cDMarDs) versus placebo in patients with active psoriatic arthritis (Psa) as part of a SPirit-P1 subgroup analysis ...
7
<p>Preferences of patients with rheumatoid arthritis regarding disease-modifying antirheumatic drugs: a discrete choice experiment</p>
... Objectives: To identify subgroups of patients with rheumatoid arthritis (RA) based on their shared preferences toward disease-modifying antirheumatic drugs (DMARDs), and to iden- tify fa[r] ...
13
Antirheumatic drugs and reproduction in women and men with chronic arthritis
... Most antirheumatic drugs have no effect on the gonads, however, as shown in table 1, they can sometimes cause fertility disorders or induce an increased risk of malformations/complications in ...modifying ...
6
Short time administration of antirheumatic drugs - Methotrexate as a strong inhibitor of osteoblast's proliferation in vitro
... fact, side effects of DMARDs are discussed controversially. It is already recognized that high dose MTX therapy causes osteoporosis in predisposed patients [16]. Just rare data exist concerning metabolic changes ...
9
Timing matters: real world effectiveness of early combination of biologic and conventional synthetic disease modifying antirheumatic drugs for treating newly diagnosed polyarticular course juvenile idiopathic arthritis
... modifying antirheumatic drugs (DMarDs) in treating children with newly diagnosed polyarticular course juvenile idiopathic arthritis (pcJia): early aggressive use of biologic DMarDs (bDMarDs) in combination ...
10
Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease modifying antirheumatic drugs (DMARDs) in the real world setting
... on patient characteristics (age, sex, race, calendar year and geographical region), behavioural factors (smoking, alcohol/drug abuse), hospitalisation within 1 year before index date, cardiovascular risk factors, ...
10
Treatment adherence to disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis
... disease-modifying antirheumatic drug; esr, erythrocyte sedimentation rate; crP, c-reactive protein; DAs28, 28-joint Disease Activity score; hAQ, health assessment questionnaire; VAs global, visual analog scale for ...
8
Assessing the effectiveness of synthetic and biologic disease-modifying antirheumatic drugs in psoriatic arthritis – a systematic review
... conventional drugs but noted a mixed treatment comparison (a method for comparing treatments in the absence of head-to-head trials) showed it was less effec- tive than TNF inhibitors; these analyses differed from ...
11
Factors associated with initial or subsequent choice of biologic disease modifying antirheumatic drugs for treatment of rheumatoid arthritis
... measured baseline DMARD use by identifying prescrip- tion fills of 21 individual non-biologic and biologic DMARDs. Non-biologic DMARDs were methotrexate (MTX), hydroxychloroquine (HCQ), sulfasalazine, lefluno- mide, gold ...
11
Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis
... A poor-quality RCT [14] that included 31 subjects with systemic JRA found that IVIG compared to conventional therapy was associated with a non-statistically significant improvement in th[r] ...
10
A Retrospective Study on Clinical Characteristics of Rheumatoid Arthritis Patients
... To study the clinical characteristics of rheumatoid arthritis (RA) patients attending the rheumatology unit in a private hospital. The demographic characteristics, laboratory parameters, comorbidities, articular ...
5
In vitro inhibition of HUVECs by low dose methotrexate – insights into oral adverse events
... 9. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, Moreland LW, O ‘ Dell J, Winthrop KL, Beukelman T, Bridges SL Jr, Chatham WW, Paulus HE, Suarez-Almazor M, Bombardier C, Dougados M, Khanna D, King CM, ...
7
Hand bone loss as an outcome measure in established rheumatoid arthritis: 2 year observational study comparing cortical and total bone loss
... (DAS28) was computed based on the erythrocyte sedimenta- tion rate [19]. Patients with a titer ≥64 of the Waaler–Rose reaction were classified as rheumatoid factor-positive. The physician's global assessment of disease ...
8
BIOLOGICS: ROLE IN RHEUMATOID ARTHRITIS
... Rheumatoid arthritis is an autoimmune disease which is chronic in nature and the exact etiology is unknown. Genetic and environmental factors disrupt the immune system which causes interaction between the T-cells and ...
9
Fluorescence optical imaging for treatment monitoring in patients with early and active rheumatoid arthritis in a 1 year follow up period
... In this subproject, we included 42 patients with early (dis- ease duration < 24 months) and active (DAS28 > 3.2) RA, who started therapy with conventional synthetic disease- modifying antirheumatic ...
12
When a patient suspected with juvenile idiopathic arthritis turns out to be diagnosed with an infectious disease – a review of Lyme arthritis in children
... anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), or intra-articular corticosteroids are rec- ommended in the United States according to the IDSA ...these drugs ...
8